Lynx Completes One-for-Two Reverse Stock Split; Solexa Merger Still Expected to Close This Month

Mar 03, 2005

NEW YORK, March 3 (GenomeWeb News) - Lynx Therapeutics said yesterday that its board of directors has approved a one-for-two reverse split of its common stock, meaning that every two shares of common stock will be reduced to one share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Main menu